New, Simplified Treatment for ALL Hepatitis C Genotypes
Two Companies Enter into Hepatitis C Drug Development Deal
By Catherine Kolonko
Achillion Pharmaceuticals has joined forces with Janssen Pharmaceuticals to develop a short-duration oral regimen to treat chronic hepatitis C, the companies announced.
Both companies have entered into an exclusive worldwide license and collaboration arrangement to develop and commercialize one or more of Achillion’s lead hepatitis C treatments (currently named ACH-3102, ACH-3422) and sovaprevir, according to a release from Janssen, which is owned by Johnson & Johnson. The aim of the partnership will be to develop a short-duration, highly effective, pan-genotypic, oral regimen for the treatment of the hepatitis C virus, states a Janssen release.
Continue reading this entire article: